DAILYPEPTIDE GUIDE
Cosmetic / Topical

GHK-Cu

Copper peptide · Copper tripeptide-1

GHK-Cu is cataloged for research literacy, with a clear separation between proposed mechanisms, marketed claims and validated human evidence.

Compare
EvidenceTier 3
RegulatoryCosmetic
SafetyUncertain or Concerning
Clinical phaseCosmetic ingredient
01

Overview

ClassCopper-binding tripeptide
Sponsor / developerProduct-specific manufacturers
Review statusReviewed
Record IDPEP-055
02

Plain-language guide

What it was designed or studied for

Used or marketed in cosmetic research and products related to Cosmetic skin care, Hair-care claims, Wound-healing research; claims depend on route and formulation.

How it works, simply

It interacts with a specific cell-signaling pathway. The measured clinical effect depends on the exact molecule, formulation, population and quality of evidence.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Topical cosmetic and injectable-market claims require route- and formulation-specific review.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Cosmetic skin care
  • Hair-care claims
  • Wound-healing research
05

Human evidence

Validated human efficacy evidence is absent, limited or not independently replicated.

Tier 3
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

MAP

Muscle & recovery profile

Each signal is scored independently from 0–5. There is no composite “best” score.

Growth relevance0/5
Preservation relevance0/5
Recovery relevance1/5
Mitochondrial support0/5
Connective tissue2/5
Human-data depth1/5
Safety confidence1/5
Evidence–hype gap3/5

Evidence classes

  • Laboratory / in-vitro evidence
  • Preclinical animal evidence
  • Marketing claim

What has been studied

  • Topical cosmetic and laboratory research examines skin and extracellular-matrix outcomes.

What is not established

  • Topical findings do not establish injectable safety, muscle recovery or systemic benefit.

Studied populations

  • Topical cosmetic populations
  • Preclinical wound models

Major limitations

  • Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
  • Findings from one population, formulation or indication should not be generalized to another.

Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.

06

Regulatory status

Cosmetic. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Uncertain or Concerning

  • Human safety data are incomplete
  • Product identity, sterility and dose consistency may be unknown
08

Interactions

Combination data are sparse. Absence of documented interaction evidence is not evidence of compatibility.

09

Treatment pattern

No validated human dosing or cycling protocol exists.

10

Manufacturing and quality

RUO and grey-market products may not establish identity, net content, sterility, endotoxin control or cold-chain integrity.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • No validated human dosing or cycling protocol exists.
  • Long-term safety and product-quality consistency remain unresolved.
14

Last reviewed

August 5, 2026 · Reviewed